P. Stuyt

发表

Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia.

A. Stalenhoef, P. Stuyt, H. Kleinjans, 1998, The Netherlands journal of medicine.

LIPOPROTEIN ASSOCIATED ISOPROTEINS IN A PATIENT WITH CHOLESTEROL EMBOLI RESULTING IN RENAL FAILURE

E. Vellenga, P. Demacker, P. Stuyt, 1983, The Lancet.

Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease.

J. Hendriks, P. Demacker, A. Stalenhoef, 1991, Scandinavian journal of clinical and laboratory investigation.

The relevance of a protein-enriched low density lipoprotein as a risk for coronary heart disease in relation to other known risk factors.

D. Swinkels, J. Hendriks, P. Demacker, 1989, Atherosclerosis.

Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolaemia.

A. Stalenhoef, A. Kroon, M. Mol, 1995, The Netherlands journal of medicine.

The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.

P. Demacker, A. Stalenhoef, M. Mol, 1990, The Netherlands journal of medicine.

PNMDEMACKER, RWB SCHADE, A F H STALENHOEF, P M J STUYT, Avan'tLAAR

P. Demacker, A. Stalenhoef, P. Stuyt, 2016 .

Influence of contraceptive pill and menstrual cycle on serum lipids and high-density lipoprotein cholesterol concentrations.

P. Demacker, A. Stalenhoef, A. van't Laar, 1982, British medical journal.

Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype.

P. Demacker, A. Stalenhoef, P. Stuyt, 1987, Journal of lipid research.

Studies on the relationship between the cholesterol content in total high density lipoprotein and its subfractions, HDL2 and HDL3 in normo- and hyperlipidemic subjects.

P. Demacker, H. Baadenhuysen, P. Stuyt, 1986, Atherosclerosis.

A missense mutation Pro157 Arg in lipoprotein lipase (LPLNijmegen) resulting in loss of catalytic activity.

M. Hayden, J. Kastelein, A. Stalenhoef, 1992, European journal of biochemistry.

EFFECTS OF INHIBITION OF CHOLESTEROL SYNTHESIS BY SIMVASTATIN ON THE PRODUCTION OF ADRENOCORTICAL STEROID HORMONES AND ACTH

P. Demacker, A. Stalenhoef, A. Hermus, 1989, Clinical endocrinology.

Why don't medical textbooks teach? The lack of logic in the differential diagnosis.

J. V. D. van der Meer, P. F. De Vries Robbé, P. Stuyt, 2003, The Netherlands journal of medicine.

Increased removal of remnants of triglyceride‐rich lipoproteins on a diet rich in polyunsaturated fatty acids

M. B. Katan, M. Katan, P. Demacker, 1991, European journal of clinical investigation.

Ultracentrifugation in swinging-bucket and fixed-angle rotors evaluated for isolation and determination of high-density lipoprotein subfractions HDL2 and HDL3.

P. Demacker, A. Stalenhoef, A. van't Laar, 1983, Clinical chemistry.

Ultracentrifugationin Swinging-Bucketand Fixed-AngleRotors Evaluatedfor Isolationand Determinationof High-DensityLipoproteinSubfractionsHDL2 and HDL3

P. Demacker, A. Stalenhoef, P. Stuyt, 1983 .

Diagnosis of Type IllHyperlipoproteinemia

P. Demacker, H. E. Vos-Janssen, A. Jansen, 1978 .

On the presumed inaccuracy of the Friedewald formula in hypertriglyceridemic plasma: a role for imprecise analysis?

P. Demacker, A. Stalenhoef, H. Willems, 1996, Clinical chemistry.

Beta-VLDL accumulation in familial dysbetalipoproteinemia is associated with increased exchange or diffusion of chylomicron lipids to apo B-100 containing triglyceride-rich lipoproteins.

P. Demacker, A. Stalenhoef, S. Bredie, 1998, Atherosclerosis.

A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.

P. Demacker, A. Stalenhoef, P. Stuyt, 1985, Atherosclerosis.

Apo E polymorphism and the removal of remnants of triglyceride-rich lipoproteins in normolipidemic subjects during a carbohydrate-rich diet.

P. Demacker, A. Stalenhoef, A. van't Laar, 1989, Clinical nutrition.

Clinical and metabolic studies in type III hyperlipoproteinemia

P. Stuyt, 1982 .

Efficacy and tolerability of simvastatin (MK-733).

A. Stalenhoef, M. Mol, P. Stuyt, 1989, The American journal of medicine.

Identification of apolipoprotein E polymorphism by using synthetic oligonucleotides.

H. Ropers, B. Wieringa, A. Stalenhoef, 1988, Journal of lipid research.

Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance.

P. de Knijff, R. Frants, L. Havekes, 1990, Journal of lipid research.

Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin.

A. Stalenhoef, J. de Graaf, P. Stuyt, 1997, The Netherlands journal of medicine.

Absence of inhibition of hepatic lipase by HDL.

P. Demacker, A. Hijmans, P. Stuyt, 1983, Atherosclerosis.

Acyclovir for herpes zoster.

J. V. D. van der Meer, P. J. van den Broek, P. Stuyt, 1994, The New England journal of medicine.

Treatment of primary hypercholesterolaemia. Short‐term efficacy and safety of increasing doses of simvastatin and pravastatin: a double‐blind comparative study

J. Kastelein, A. Stalenhoef, A. Kroon, 1993, Journal of internal medicine.

Long-term treatment of type III hyperlipoproteinemia with clofibrate.

P. Demacker, A. van't Laar, P. Stuyt, 1981, Atherosclerosis.

Long‐term effects of simvastatin in familial dysbetalipoproteinaemia

A. Stalenhoef, M. Mol, P. Stuyt, 1991, Journal of internal medicine.

Serum lipids, lipoproteins and apolipoprotein E phenotypes in relatives of patients with type III hyperlipoproteinaemia

P. Demacker, P. Stuyt, A. Laar, 1984, European journal of clinical investigation.

Familial chylomicronemia caused by a novel type of mutation in the APOE-CI-CIV-CII gene cluster encompassing both the APOCII gene and the first APOCIV gene mutation: APOCII-CIV(Nijmegen).

R. Frants, A. Stalenhoef, J. de Graaf, 2000, Biochemical and biophysical research communications.

Type III hyperlipoproteinaemia: the turnover rate of plasma triglycerides and the response to clofibrate.

P. Demacker, A. Stalenhoef, J. Lutterman, 1982, The Netherlands journal of medicine.

Towards organizational development for sustainable high-quality medical teaching

C. Fluit, S. Bolhuis, R. Engbers, 2013, Perspectives on medical education.

[The physician as teacher. Ways to measure the quality of medical training].

C. Fluit, S. Bolhuis, R. Laan, 2011, Nederlands tijdschrift voor geneeskunde.

Clinical Problem Analysis (CPA): A Systematic Approach to Teaching Complex Medical Problem Solving

E. Custers, P F De Vries Robbé, E J Custers, 2000, Academic medicine : journal of the Association of American Medical Colleges.

HYPERLIPOPROTEINAEMIA TYPE V AND APOLIPOPROTEIN E4

P. Demacker, A. Stalenhoef, P. Stuyt, 1982, The Lancet.

Pancreatitis induced by oestrogen in a patient with type I hyperlipoproteinaemia.

P. Demacker, A. Stalenhoef, P. Stuyt, 1986, British medical journal.

RELATING TEACHING QUALIFICATIONS

R. Sluiter, C. Fluit, S. Bolhuis, 2018 .

Relations between policy for medical teaching and basic need satisfaction in teaching

R. Sluiter, C. Fluit, S. Bolhuis, 2015, Advances in health sciences education : theory and practice.

Relations between policy for medical teaching and basic need satisfaction in teaching

R. Sluiter, C. Fluit, S. Bolhuis, 2014, Advances in Health Sciences Education.

Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).

P. Demacker, A. Stalenhoef, M. Mol, 1990, The American journal of medicine.

Application and comparison of different criteria used for the diagnosis of type III hyperlipoproteinemia.

H. E. Vos-Janssen, A. Jansen, P. Stuyt, 1978, Clinical chemistry.

CHOLESTEROL SYNTHESIS INHIBITORS IN HYPERLIPIDAEMIA

A. Stalenhoef, M. Mol, P. Stuyt, 1988, The Lancet.